Clinical trials: Recurrent Tumor
Malignant Glioma, Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas.
- Trial name
- NCT01266031
- Testing
- vorinostat, bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
The main purpose of this study is to see how well the combination of Abraxane and gemcitabine works in people with advanced adenocarcinoma NSCLC who have already had treatment for their disease.
- Trial name
- NCT02303977
- Testing
- Abraxane, Gemcitabine
- Volunteers
- 37 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Liver Transplantation
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection.
- Trial name
- NCT01428700
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Myeloproliferative Disorders, Leukemia
Pyroxamide in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00042900
- Testing
- pyroxamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Phase IIB TL + YCWP + DC in Melanoma
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants.
- Trial name
- NCT02301611
- Testing
- TLPLDC
- Where
- 18 sites in United States
- Volunteers
- 187 people
- Sponsor
- Elios Therapeutics, LLC
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
This phase I trial studies the side effects and best dose of STAT inhibitor OPB-111077 when given together with decitabine and venetoclax in treating patients with acute myeloid leukemia that does not respond to treatment…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03063944
- Testing
- STAT Inhibitor OPB-111077, Decitabine, Venetoclax
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Refractory Ascites in Children With Cirrhosis
Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.
Refractory ascites is seen in 17% of cirrhotic patients with the 1year mortality rate being high, upto 20-50% [1]. The pathogenesis of cirrhotic ascites includes release of vasodilatory molecules like nitric oxide, damage…
- Trial name
- NCT05084534
- Testing
- Midodrine, Standard medical treatment
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer.
- Trial name
- NCT00054132
- Testing
- Bevacizumab, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Tract Infections, Kidney Stone
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
This study will assess patients who have recurrent urinary tract infections and kidney stones which are not blocking the kidney or causing other problems.
- Trial name
- NCT04495699
- Testing
- None - observational
- Where
- 6 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Vanderbilt University Medical Center
Relapsed or Refractory Hematologic Malignancies
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
- Trial name
- NCT06252298
- Testing
- SCTC21C
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Sinocelltech Ltd.
Hodgkin's Disease, Lymphoma
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1.
- Trial name
- NCT00129753
- Testing
- Alemtuzumab (Campath-1H)
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Clostridium Difficile Infection
Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies
The objective of the present study is to derive a high-risk R-ICD prediction rule and a prospective implementation of this prediction rule.
- Trial name
- Clostri_Score (NCT04187430)
- Testing
- Retrospective, Prospective
- Where
- Spain
- Volunteers
- 513 people
- Sponsor
- Emilio Bouza
Brain and Central Nervous System Tumors
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387400
- Testing
- everolimus, temozolomide, microarray analysis
- Where
- 9 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002944
- Testing
- carboplatin, lomustine, procarbazine hydrochloride
- Where
- 204 sites in United States, Australia and 4 more
- Volunteers
- 428 people
- Sponsor
- Children's Oncology Group
Bronchiolitis Acute, Wheezing
The Role of Vitamin D and Vitamin D Receptor in Recurrent Wheezing in Children With Bronchiolitis: Immunological Association With T-lymphocyte Mitochondrial Mass
A prospective study will be conducted involving children under 2 years of age hospitalized for bronchiolitis during the period 2025-2026.
- Conditions
- Bronchiolitis Acute, Wheezing, RSV
- Trial name
- NCT07700134
- Testing
- No Intervention: Observational Cohort
- Where
- Greece
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Glioma
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
Gliomas represent the most frequent primary brain tumor, with 2,500 to 3,000 new cases per year in France. Their diagnosis, although highly complex, is essential for determining patient management.
- Trial name
- circTeloDIAG (NCT04931732)
- Testing
- ctDNA analysis
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, RFA
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, RFA, TACE
- Trial name
- NCT01415063
- Testing
- RFA, TACE-RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
First Trimester Pregnancy, Fetal Heart Activity Absent
Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin
The finding that ischemia-modified albumin (IMA) is increased in pre-eclamptic pregnancy suggests a role for IMA as a potential biomarker for abnormal placental development related to miscarriage.This study was undertaken to…
- Conditions
- First Trimester Pregnancy, Fetal Heart Activity Absent, Absence of Fetal Pole on Ultrasonographic Examination.
- Trial name
- IMA (NCT01988740)
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.